1. Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
   Matthew D. Poskus et al, 2024, Cellular and Molecular Bioengineering CrossRef
2. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
   Hee-Jeong Choi et al, 2023, Frontiers in Pharmacology CrossRef
3. Syringin as TGF-βR1, HER2, EGFR, FGFR4 Kinase, and MMP-2 Inhibitor and Potential Cytotoxic Agent against ER+ Breast Cancer Cells
   Ross D. Vasquez et al, 2023, Current Enzyme Inhibition CrossRef